Viral gastroenteritis

Current Opinion in Infectious Diseases

Volumn 12, Issue 5, 1999, Pages 447-457

  Hart, C Anthony ^a   Cunliffe, Nigel A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; LIVE VACCINE; POLIOMYELITIS VACCINE; PROBIOTIC AGENT; PROSTAGLANDIN A; SIMIAN ROTAVIRUS VACCINE;

ASTROVIRUS; BACTERIOPHAGE; BREAST FEEDING; CALICIVIRUS; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG COST; GASTROENTERITIS; HUMAN; IMMUNITY; IMMUNOLOGY; INTESTINE FLORA; INTUSSUSCEPTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; REHYDRATION; REVIEW; ROTAVIRUS; SEASONAL VARIATION; SIDE EFFECT; UNITED STATES; VIRUS GENOME; VIRUS INFECTION; VIRUS PARTICLE; VIRUS TYPING;

EID: 0032762840     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199910000-00007     Document Type: Review

References (91)

1. 1 Plunkett G, Rose D, Durfee T, Blattner F. Sequence of shiga toxin-2 phage 933W from Escherichia coli O157:H7: shiga toxin as a phage late gene product. J Bacteriol 1999; 181:1767-1778.
2. 2 Trucksis M, Galen JE, Michalski J, Fasano A, Kaper JB. Accessory cholera toxin (Ace), the third toxin of a Vibrio cholerae virulence cassette. Proc Natl Acad Sci USA 1993; 90:5267-5271.
3. 3 Murray CJ, Lopez AD. Global mortality disability and the contribution of risk factors: global burden of disease study. Lancet 1997; 349:1436-1442.
4. 4 Bern C, Martinez J, de Zoysa I, Glass RI. The magnitude of the global problem of diarrhoeal disease: a ten year update. Bull WHO 1992; 70:705-714.
5. 5 Desselberger U. Viral gastroenteritis. Curr Opin Infect Dis 1998; 11:565-575. A very useful review of the viruses that infect the human gastrointestinal tract.
6. 6 Huilan S, Zhen LG, Mathan MM, Mathew MM, Olarte J, Espejo R, et al. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. Bull WHO 1992; 69:549-555.
7. 7 Qiao HP, Nilsson M, Abreu ER, Hedlund KO, Johansen K, Zaori G, et al. Viral diarrhea in children in Beijing, China. J Med Virol 1999; 57:390-396.
8. 8 Pajé-Vilar E, Co BG, Caradang EH, Raymundo A, Lagamayo E, Lavadia E, et al. Non-bacterial diarrhoea in children in the Philippines. Ann Trop Med Parasitol 1994; 88:53-58.
9. 9 Pavone R, Schinaia N, Hart CA, Getty B, Molyneux M, Borgstein A. Viral gastroenteritis in children in Malawi. Ann Trop Paediatr 1990; 10:15-20.
10. 10 Jamieson FB, Wang EL, Bain C, Good J, Duckmanton L, Petric M. Human torovirus: a new nosocomial gastrointestinal pathogen. J Infect Dis 1998; 178: 1263-1269. Torovirus was detected more frequently than rotavirus in childhood gastroenteritis (35 versus 8%) and more often than in asymptomatic control subjects (14.5%).
11. 11 Maldonaldo Y, Cantwell M, Old M, Hill D, de la Luz Sanchez M, Logan L, et al. Population-based prevalence of symptomatic and asymptomatic astrovirus infection in rural Mayan infants. J Infect Dis 1998; 178:334-339. In a population-based survey in Mexico, astrovirus was the most important viral enteropathogen, with peaks of infection in March and May.
12. 12 Gaggero A, O'Ryan M, Noel JS, Glass RI, Monroe SS, Mamani N, et al. Prevalence of astrovirus infection among Chilean children with acute gastroenteritis. J Clin Microbiol 1998; 36:3691-3693.
13. 13 Barnes GL, Uren E, Stevens KB, Bishop RF. Etiology of acute gastroenteritis in hospitalized children in Melbourne, Australia from April 1980 to March 1993. J Clin Microbiol 1998; 36:133-138.
14. 14 Lew JF, Moe CL, Monroe SS, Allen JR, Harrison BM, Forrester BD, et al. Astrovirus and adenovirus associated with diarrhea in children in day care settings. J Infect Dis 1991; 164:673-678.
15. 15 Blacklow NR, Greenberg HB. Viral gastroenteritis. N Engl J Med 1991; 325:252-264.
16. 16 Estes MK. Rotaviruses and their replication. In: Field's virology. Fields BN, Knipe DM, Howley PM. (editors). Philadelphia: Lippincott Raven; 1996. pp. 1625-1655.
17. 17 Hart CA, Cunliffe NA. Viral gastroenteritis. Curr Opin Infect Dis 1997; 10:408-413.
18. 18 Ball JM, Tian P, Zeng CQY, Morris AP, Estes MK. Age-dependent diarrhea induced by a rotavirus non-structural glycoprotein. Science 1996; 272:101-104.
19. 19 Zang MD, Zeng CQY, Dong YJ, Ball JM, Saif LJ, Morris AP, et al. Mutations in rotavirus non-structural glycoprotein NSP4 are associated with altered virus virulence. J Virol 1998; 72:3666-3672. Comparisons of NSP4 sequences from two pairs of virulent and attenuated porcine rotaviruses suggest that amino acid replacements between positions 131 and 140 alter virulence.
20. 20 Angel J, Tang BZ, Feng NG, Greenberg HB, Bass D. Studies of the role for NSP4 in the pathogenesis of homologous murine rotavirus diarrhea. J Infect Dis 1998; 177:455-458. No consistent or significant changes in deduced amino acid sequences of NSP4 were found between virulent and avirulent murine rotavirus strains. Homologous knockout mice (missing the cystic fibrosis transmembrane conductance regulator), which do not respond to known intestinal secretagogues, exhibited as much diarrhoea as cystic fibrosis transmembrane conductance regulator-positive littermates when infected with rotavirus.
21. 21 Burns NW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996; 272:104-107.
22. 22 Feng NG, Vo PT, Chung D, Vo TVP, Hoshino Y, Greenberg HB. Heterotypic protection following oral immunization with live heterologous rotaviruses in a mouse model. J Infect Dis 1997; 175:330-341.
23. 23 Cunliffe NA, Gondwe JS, Broadhead RL, Molyneux ME, Woods PA, Bresee JS, et al. Rotavirus G and P types in children with acute diarrhea in Blantyre, Malawi from 1997 to 1998: predominance of novel P[6]G8 strains. J Med Virol 1999; 57:308-312. The first report of P[6]G8 and P[4]G8 rotaviruses, which were responsible for 51% of all rotavirus infection in Malawian infants.
24. 24 Nakata S, Gatheru Z, Ukae S, Adachi N, Kobayashi N, Honma S, et al. Epidemiological study of the G serotype distribution of group A rotaviruses in Kenya from 1991 to 1994. J Med Virol 1999; 58:296-303. A total of 2.2% of the typed rotaviriis were G8 P1B[4]; of the rest 42.3% were G4, 23.7 G1, 16.7 G2 and 0.6% G3, with some unusual G/P combinations.
25. 25 Mphahlele MJ, Peenze I, Steele AD. Rotavirus strains bearing the VP4P[14] genotype recovered from South African children with diarrhoea. Arch Virol 1999; 144:1027-1034. This study describes the isolation of a rare G1P[14] rotavirus of subgroup II with a long electropherotype.
26. 26 Nakagomi T, Horie Y, Koshimura Y, Greenberg HB, Nakagomi O. Isolation of a human rotavirus strain with a super-short RNA pattern and a new P2 subtype. J Clin Microbiol 1999; 37:1213-1216. This study reports a rare example of a super-short electropherotype isolated in Japan. It was type G1 P2[4] but differed in its VP4 hypervariable region from P2A and P2B, and is thus proposed as P2C[4].
27. 27 Ciarlet M, Estes MK. Human and most animal rotavirus strains do not require the presence of sialic acid on the cell surface for efficient inactivity. J Gen Virol 1999; 80:943-948. Neuraminidase treatment of MA104 cells that removed sialic acid residues did not decrease the infectivity of 67% of animal rotaviruses and none of 17 human rotaviruses.
28. 28 Rolsma MD, Kuhlenschmidt TB, Gelberg HB, Kuhlenschmidt MS. Structure and function of a ganglioside receptor for porcine rotavirus. J Virol 1998; 72:9079-9081.
29. 29 Ludert JE, Mason BB, Angel J, Tang BZ, Hoshino Y, Feng NG, et al. Identification of mutations in the rotavirus VP4 that alter sialic acid-dependent infection. J Gen Virol 1998; 79:725-729. Amino acid substutions in RRV VP4 at position 150 (Gly-→Glu) or 187 (Lys→Arg) render infectivity sialic acid independent.
30. 30 Kirkwood CD, Bishop RF, Coulson BF. Attachment and growth of human rotaviruses RV-3 and S/2/85 in CaCo-2 cells depend on VP4. J Virol 1998; 72:9348-9352.
31. 31 Ijaz MK, Nur el Kamal MSA, Udman FK, Redmond MJ, Attah-Polu SK, Dent D, et al. Inhibition of rotavirus infection in vitro and in vivo by a synthetic peptide from VP4. Vaccine 1998; 16:916-920. Pre-treatment of MA104 cells with a synthetic peptide corresponding to VP4 amino acid residues 232-255 inhibited both binding and plaque formation by bovine rotavirus.
32. 32 Denisova E, Dowling W, LaMonica R, Shaw R, Scarlata S, Ruggeri F, et al. Rotavirus capsid protein VP5* permeabilizes membranes. J Virol 1999; 73:3147-3153. VP5* but not VP4 or VP8* permeabilized liposomes. This was inhibited by anti-VP5*, but was not dependent on divalent cations or cholesterol in the membrane.
33. 33 Batt RM, Embaye H, van de Waal S, Burgess D, Edwards GB, Hart CA. Application of organ culture of small intestine to the investigation of enterocyte damage by equine rotavirus. J Pediatr Gastroenterol Nutr 1995; 20:326-332.
34. 34 Jourdan N, Brunet JP, Sapia C, Blais A, Cotte-Laffitte J, Forestier F, et al. Rotavirus infection reduces sucrase-isomaltase expression in human intestinal epithelial cells by perturbing protein targeting and organization of microvillar cytoskeleton. J Virol 1998; 72:7228-7236. A very useful study.
35. 3+ and verapamil.
36. 2+ concentrations. Virology 1998; 252:17-27. An excellent study.
37. 37 Davidson GP, Barnes GL. Structural and functional abnormalities of the small intestine in infants and young children with rotavirus enteritis. Acta Paediatr Scand 1979; 68:181-186.
38. 38 Velasquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Campbell S, et al. Rotavirus infection in infants as protection against subsequent infection. N Engl J Med 1996; 355:1022-1028.
39. 39 Moulton LH, Staat MA, Santosham M, Ward RL. The protective effectiveness of natural rotavirus infection in an American Indian population. J Infect Dis 1998; 178:1562-1566. Infection with G3 rotavirus gave 91% protection from subsequent infection with G3 virus. A heterotypic effectiveness of 50% was observed.
40. 40 Ramachandran M, Vij A, Kumar R, Das BR, Gentsch JR, Bhan MK, et al. Lack of maternal antibodies to P-serotypes may predispose neonates to infection with unusual rotavirus strains. Clin Diagn Lab Immunol 1998; 5:527-530.
41. 41 Newman RD, Grupp-Phelan J, Shay DK, Davis RL. Perinatal risk factors for infant hospitalisation with viral gastroenteritis. Pediatrics 1999; 103:E31-E36.
42. 42 Casola A, Estes MK, Crawford SE, Ogra PL, Ernst PB, Garofalo RP, et al. Rotavirus infection of cultured intestinal cells induces secretion of CXC and GC chemokines. Gastroenterology 1998; 114:947-955.
43. 43 Djuretic T, Ramsay M, Gay N, Wall P, Ryan M, Fleming D. An estimate of the proportion of diarrhoeal disease episodes seen by general practitioners attributable to rotavirus in children under 5 years of age in England and Wales. Acta Paediatr 1999; 88 (S426):38-41.
44. 44 Cunliffe NA, Kilgore PE, Bresee JS, Steele AD, Luo N, Hart CA, et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull WHO 1998, 76:525-537. A review of available data on rotavirus diarrhoea, seasonality and P and G types in Africa.
45. 45 Koopmans M, Brown D. Seasonality and diversity of group A rotavirus in Europe. Acta Paediatr 1999; 88: 14-19.
46. 46 Purohit SG, Kelkar SD, Simha V. Time series analysis of patients with rotavirus diarrhoea in Pune, India. J Diarrh Dis Res 1998; 16:74-83.
47. 47 Tabassum S, Shears P, Hart CA. Genomic characterization of rotavirus strains obtained from hospitalized children with diarrhoea in Bangladesh. J Med Virol 1994; 43:50-56.
48. 48 Gentsch JR, Woods PA, Ramachandran M, Das BK, Leite JP, Alfieri A, et al. Reviews of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996; 174 (Suppl. 1):S30-S36.
49. 49 Gault E, Chikhi-Brachet R, Delon S, Schnepe N, Albiges L, Grimprel E, et al. Distribution of human rotavirus G-types circulating in Paris, France during the 19971998 epidemic: high prevalence of type G4. J Clin Microbiol 1999; 37:2373-2375.
50. 50 O'Mahony T, Foley B, Morgan S, Morgan JG, Hill C. VP4 and VP7 genotyping of rotavirus samples recovered from infected children in Ireland over a 3-year period. J Clin Microbiol 1999; 37:1699-1703.
51. 51 Unicomb LE, Podder G, Gentsch JR, Woods PA, Hasan KZ, Faruque ASG, et al. Evidence of high frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995. J Clin Microbiol 1999; 37:1885-1891.
52. 52 Santos N, Lima RCC, Pereira CFA, Gouvea V. Detection of rotavirus types G8 and G10 among Brazilian children with diarrhea. J Clin Microbiol 1998; 36:2727-2729.
53. 53 Zao CL, Yu WN, Kao CL, Taniguchi K, Lee CY, Lee CN. Sequence analysis of VP1 and VP7 genes suggests the occurrence of a reassortant G2 rotavirus responsible for an epidemic of gastroenteritis. J Gen Virol 1999; 80:1407-1415.
54. 54 Cox MJ, James VLA, Azevedo RS, Massad E, Medley GF. Infection with group C rotavirus in a suburban community in Brazil. Trop Med Int Health 1998; 3:891-895.
55. 55 Souza DFC, Kiselius JJ, Ueda M, Gabbay YB, Carmona RCC, Timenetsky MDST, et al. An outbreak of group C rotavirus gastroenteritis among adults living in Velentim Gentil, Sao Paulo State, Brazil. J Diarrh Dis Res 1998; 16:59-65.
56. 56 Krishnan T, Sen A, Sinha Choudhury J, Das S, Naik TN, Bhattacharya SK. Emergence of adult diarrhoea rotavirus in Calcutta, India. Lancet 1999; 353:380-381. The first description of group B adult diarrhoea rotaviruses outside China.
57. 57 Bonno M, Higashigawa M, Nakano I, Miyahara M, Azuma E, Komada Y, et al. Acute myositis with transient decrease of albumin, immunoglobulin and complement following rotavirus gastroenteritis. Acta Paediatr Japon 1998; 40:82-84.
58. 58 Takahashi S, Oki J, Miyamoto A, Koyano S, Ito K, Azuma H, et al. Encephalopathy associated with haemophagocytic lymphohistiocytosis following rotavirus infection. Eur J Paediatr 1999; 158:133-137.
59. 59 Chou IC, Tsai CH, Tsai FJ. Rotavirus associated with poliomyolitis-like syndrome. Pediatr Infect Dis J 1998; 17:930-931.
60. 60 Hongou K, Konishi T, Yagi S, Araki K, Miyawaki T. Rotavirus encephalitis mimicking afebrile benign convulsions in infants. Pediatr Neurol 1998; 18:354-357. Rotavirus genome (G4P[8]) was detected in the cerebrospinal fluid. Recovery was uneventful with no sequelae.
61. 61 Richardson S, Grimwood K, Gorrell R, Palombo E, Barnes G, Bishop R. Extended excretion of rotavirus after severe diarrhoea in young children. Lancet 1998; 351:1844-1848. Prolonged excretion (25-57 days) was found in 30% of children with severe rotavirus diarrhoea.
62. 62 Sarker SA, Casswall TH, Mahalanabis D, Alam DH, Albert MJ, Brussow H, et al. Successful treatment of rotavirus diarrhoea in children with immunoglobulin from immunized cows. Pediatr Infect Dis J 1998; 17:1149-1154.
63. 63 Superti F, Amici C, Tinari A, Donnelli G, Santoro MG. Inhibition of rotavirus replication by prostaglandis A: evidence for a block of virus maturation. J Infect Dis 1998; 178:564-568.
64. 64 Newbury DS, Peterson JA, Ruiz-Palacios GM, Matson DO, Morrow AL, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. Lancet 1998; 351:1160-1164.
65. 65 MacFarlane GT, Cummings JH. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health. BMJ 1999; 318:999-1003. A balanced review of probiotics.
66. 66 Perdone CA, Bernabeu AO, Postaire ER, Bouley CF, Reinert P. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN 114-001) on acute diarrhoea in children attending day-care-centres. Int J Clin Pract 1999; 53:179-184.
67. 67 Haschke F, Wang W, Ping GZ, Varavithya W, Podhipak A, Rochat F, et al. Clinical trials prove the safety and efficacy of the probiotic strain Bifidobacterium Bb12 in follow-up formula and growing up milks. Monatsschrift Kinderheilkunde 1998; 146:S26-S30.
68. 68 Takala AK, Koskenniemi E, Joensuu J, Makela M, Vesikari T. Economic evaluation of rotavirus vaccinations in Finland: randomized double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin Infect Dis 1998; 27:272-278.
69. 69 Marwick AJ, Rennels MB, Zito ET, Wade MS, Mack ME. Oral tetravalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine. Pediatr Infect Dis J 1998; 17:913-918.
70. 70 Centers for Disease Control. Intussusception among recipients of rotavirus vaccine United States 1998-1999. MMWR 1999; 48:577-581.
71. 71 Madore HP, Estes MK, Zarley CD, Hu B, Parsons S, Digravio D, et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 1999; 2461-2471. Virus-like particles incorporating bovine rotavirus VP2 (for stability) bovine VP6 and simian VP7 (93) when injected into mice produced good serum neutralizing antibody levels.
72. 72 Chen SC, Jones DH, Eynan EF, Farrar GH, Clegg JCS, Greenberg HB, et al. Protective Immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998; 72:5757-5761. Oral administration to mice of encapsulated rotavirus VP6 DNA elicited both anti-rotavirus serum antibodies and intestinal IgA and showed protection against infection.
73. 73 Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, et al. Efficacy of a live attenuated human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999; 354:287-290. This study describes the successful trial of a potential new rotavirus vaccine.
74. 74 Gibson CA, Chen J, Monroe SA, Denison MR. Expression and processing of non-structural proteins of the human astroviruses. Adv Exp Med Biol 1998; 440:387-391.
75. 75 Koopmans MPG, Bijen MHL, Monroe SS, Vinje J. Age stratified seroprevalence of neutralizing antibodies to astrovirus types 1 to 7 in humans in the Netherlands. Clin Diagn Lab Immunol 1998; 5:33-37.
76. 76 Molberg O, Lundin KEA, Nilsen EM, Scott H, Kett K, Brandtzaeg P, et al. HLA restriction patterns of gliadin-and astrovirus-specific CD4(+) T cells isolated in parallel from the small intestine of celiac disease patients. Tissue Antigens 1998; 52:407-415.
77. 77 Steele AD, Basetse HR, Blacklow NR, Herrmann JE. Astrovirus infection in South Africa: a pilot study. Ann Trop Paediatr 1998; 18:315-319. Astrovirus was detected in 7% of diarrhoeic stools compared with 20% rotavirus and 3% adenovirus 40/41.
78. 78 Miossec L, LeGuyader F, Haugarreau L, Camps MA, Pommepuy M. Possible relationship between a winter epidemic of acute gastroenteritis in France and viral contamination of shellfish. J Shellfish Res 1998; 17:1661-1664.
79. 79 Egglestone SI, Caul EO, Vipond IB, Darville JM. Absence of human astrovirus RNA in sewage and environmental samples. J Appl Microbiol 1999; 86:709-714.
80. 80 Cubitt WD, Mitchell DK, Carter MJ, Willcocks MM, Holzel H. Application of electronmicroscopy, enzyme immunoassay and RT-PCR to monitor an outbreak of astrovirus type 1 in a paediatric bone marrow transplant unit. J Med Virol 1999; 57:313-321.
81. 81 Mustafa H, Palombo EA, Bishop RF. Improved sensitivity of astrovirus specific RTPCR following culture of stool samples in CaCo-2 cells. J Clin Virol 1998; 11:103-107.
82. 82 Hale AD, Crawford SE, Ciarlet M, Green J, Gallimore C, Brown DWG, et al. Expression and self assembly of Grimsby virus: antigenic distinction from Norwalk and Mexico viruses. Clin Diagn Lab Immunol 1999; 6:142-145.
83. 83 Parashar UD, Dow L, Frankhauser RL, Humphrey CD, Miller J, Ando T, et al. An outbreak of viral gastroenteritis associated with consumption of sandwiches: implications for the control of transmission by food handlers. Epidemiol Infect 1998; 121:615-621.
84. 84 Dastjerdi AM, Green J, Galtimore CI, Brown DWG, Bridger JC. The bovine Newbury agent-2 is genetically more closely related to human SRSVs than to animal caliciviruses. Virology 1999; 254:1-5.
85. 85 Liu BL, Lambden PR, Gunther H, Otto P, Elschner M, Clarke IN. Molecular characterization of a bovine enteric calicivirus: relationship to the Norwalk-like viruses. J Virol 1999; 73:819-825.
86. 86 Nakata S, Honma S, Numata K, Kogawa K, Ukae S, Adachi N, et al. Prevalence of human calicivirus infections in Kenya as determined by enzyme immunoassays for three genogroups of virus. J Clin Microbiol 1998; 36:3160-3163.
87. 87 O'Ryan ML, Vial PA, Mamani N, Jiang X, Estes MK, Ferrecio C, et al. Seroprevalence of Norwalk virus and Mexico virus in Chilean individuals: assessment of independent risk factors for antibody acquisition. Clin Infect Dis 1998; 27:789-795.
88. 88 Honma S, Nakata S, Numata K, Kogawa K, Yamashita T, Oseto M, et al. Epidemiological study of prevalence of genogroup II human calicivirus (Mexico virus) infections in Japan and Southeast Asia as determined by enzyme-linked immunosorbent assays. J Clin Microbiol 1998; 36:2481-2484.
89. 89 Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. Identification of a distinct common strain of 'Norwalk-like viruses' having a global distribution. J Infect Dis 1999; 179:1334-1344. Demonstration that the same Norwalk-like virus was present in North and South America, Europe, Asia and Australasia.
90. 90 Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998; 72:1345-1353.
91. 91 Giordano MO, Martinez LC, Rinaldi D, Guinard S, Naretto E, Casero R, et al. Detection of picobimavirus in HIV-infected patients with diarrhea in Argentina. J AIDS Hum Retrovirol 1998; 18:380-383.